PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Metered dose and soft mist inhalers - Market size and forecast 2018-2023 • Dry powder inhalers - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Rising integration of AI and adoption of IoT • Business strategies • Growing internet connectivity and use of smartphone devices PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca Plc • GlaxoSmithKline Plc • Novartis AG • OPKO Health Inc. • Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global medical devices market Exhibit 03: Segments of global medical devices market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Hospital admission rate for asthma and COPD in adults in 2015 per 100,000 population Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: Metered dose and soft mist inhalers - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Metered dose and soft mist inhalers - Year-over-year growth 2019-2023 (%) Exhibit 23: Dry powder inhalers - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Dry powder inhalers - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Asia - Year-over-year growth 2019-2023 (%) Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 36: ROW - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Percentage of population with self-reported COPD aged 15 and over in 2014 (Europe) Exhibit 40: Impact of drivers and challenges Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: AstraZeneca Plc - Vendor overview Exhibit 47: AstraZeneca Plc - Product segments Exhibit 48: AstraZeneca Plc - Organizational developments Exhibit 49: AstraZeneca Plc - Geographic focus Exhibit 50: AstraZeneca Plc - Segment focus Exhibit 51: AstraZeneca Plc - Key offerings Exhibit 52: AstraZeneca Plc - Key customers Exhibit 53: GlaxoSmithKline Plc - Vendor overview Exhibit 54: GlaxoSmithKline Plc - Business segments Exhibit 55: GlaxoSmithKline Plc - Organizational developments Exhibit 56: GlaxoSmithKline Plc - Geographic focus Exhibit 57: GlaxoSmithKline Plc - Segment focus Exhibit 58: GlaxoSmithKline Plc - Key offerings Exhibit 59: GlaxoSmithKline Plc - Key customers Exhibit 60: Novartis AG - Vendor overview Exhibit 61: Novartis AG - Business segments Exhibit 62: Novartis AG - Organizational developments Exhibit 63: Novartis AG - Geographic focus Exhibit 64: Novartis AG - Segment focus Exhibit 65: Novartis AG - Key offerings Exhibit 66: Novartis AG - Key customers Exhibit 67: OPKO Health Inc. - Vendor overview Exhibit 68: OPKO Health Inc. - Business segments Exhibit 69: OPKO Health Inc. - Organizational developments Exhibit 70: OPKO Health Inc. - Geographic focus Exhibit 71: OPKO Health Inc. - Key offerings Exhibit 72: OPKO Health Inc. - Key customers Exhibit 73: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 74: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 75: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 76: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 77: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 78: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 79: Validation techniques employed for market sizing Exhibit 80: Definition of market positioning of vendors

AstraZeneca Plc, GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., and Teva Pharmaceutical Industries Ltd.